


**Product Name** : Riviciclib  
**Cat. No.** : PC-61279  
**CAS No.** : 920113-03-7  
**Molecular Formula** : C<sub>21</sub>H<sub>20</sub>ClNO<sub>5</sub>·HCl  
**Molecular Weight** : 438.3  
**Target** : Cyclin-dependent Kinase (CDK)  
**Solubility** : 10 mM in DMSO



## Biological Activity

Riviciclib (P276-00 hydrochloride) is a potent **CDK** inhibitor with IC<sub>50</sub> of 79 nM, 63 nM and 20 nM for Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, respectively.

Riviciclib (P276-00 hydrochloride) weakly inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk6/cyclin D3 and Cdk7/cyclin H with IC<sub>50</sub> of 0.2-3 μM.

Riviciclib (P276-00 hydrochloride) shows potent antiproliferative effects against various human cancer cell lines (IC<sub>50</sub>=200-800 nM).

Riviciclib (P276-00 hydrochloride) induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.

## References

Joshi KS, et al. *Mol Cancer Ther.* 2007 Mar;6(3):918-25.

Joshi KS, et al. *Mol Cancer Ther.* 2007 Mar;6(3):926-34.

Raje N, et al. *Leukemia.* 2009 May;23(5):961-70.

Rathos MJ, et al. *J Transl Med.* 2012 Aug 8;10:161.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com